How Martha was paid
$22.9M in total for 2026, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Geoff MarthaChairman and Chief Executive Officer | $1,399,039 | — | $13,672,200 | $5,175,559 | $2,307,200 | $386,255 | $22,940,252 |
| Thierry PiétonEVP, Chief Financial Officer | $849,648 | $2,000,000 | $3,170,470 | $1,200,139 | $963,050 | $404,079 | $8,587,387 |
| Brett WallFormer EVP & President, Neuroscience Portfolio | $799,519 | — | $3,566,703 | $1,350,152 | $824,000 | $381,050 | $6,921,425 |
| Mike MarinaroEVP & President Medical Surgical Portfolio & Americas | $819,616 | — | $3,566,703 | $1,350,152 | $971,290 | $125,075 | $6,832,836 |
| Michelle QuinnEVP, General Counsel and Secretary | $600,000 | $1,100,000 | $3,481,600 | $750,082 | $617,423 | $170,065 | $6,719,170 |
What changed and why
- $22.9M$22,940,252: CEO total compensation, up from $21,240,058 in 2025.
- $20.4M$20,444,258: Maximum potential FY26 PSU payout for CEO Geoff Martha.
- $2M$2,000,000: Cash sign-on award paid to CFO Thierry Piéton for forfeited prior-employer compensation.
- $1.1M$1,100,000: Cash sign-on award paid to General Counsel Michelle Quinn for forfeited prior-employer compensation.
- 93.45%93.45%: Shareholder approval of named executive officer compensation at the 2025 annual meeting.
- $36.4B5.8%: FY26 organic revenue growth, alongside $36.4 billion in reported revenue.
Other Medtronic proxy statements
- 2025 proxy statement
Geoffrey S. Martha paid $21.2M (+6% on the year), pay ratio 309:1.
Filed Aug 25, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.